News
Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...
Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...
Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.
COVID-19 cases are rising in half of U.S. states. What to know about COVID trends and the new Stratus and Nimbus variants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results